Doctors track MS patients switching to newer pill therapy

This study observed 104 people with relapsing-remitting multiple sclerosis (RRMS) in Italy who switched from their first or second disease-modifying therapy to a newer oral medication called ozanimod. Researchers tracked why patients switched (like side effects or the treatment not working well), how the switch was managed, and monitored disease activity and safety over time. The goal was to understand how this medication change works in everyday clinical practice outside of a controlled trial.